期刊文献+

香豆素类抗凝药的临床评价与合理应用 被引量:6

Clinical Evaluation and Rational Use of Coumarin Anticoagulants
下载PDF
导出
摘要 目的:对香豆素类抗凝药的临床应用现状进行评价和研究。方法:查阅国内外近年来的相关文献,对香豆素类抗凝药的代表药物华法林的药学基础、临床应用及研究进展进行总结和分析。结果及结论:随着医生和患者对华法林的认识不断加深,华法林将在口服抗凝治疗中发挥更加积极的作用;国内对华法林的使用有待更加规范化。 OBJECTIVE: To study and evaluate the status quo of the clinical use of coumarin anticoagulants. METHODS: The related literature both home and abroad in recent years were collected, and the pharmaceutical basis, clinical use and development of warfarin (a typical product of coumarin anticoagulants) were summarized and analyzed. RESULTS & CONCLUSION: With the increased awareness of both practitioners and patients on warfarin, warfarin will play a more active role in oral antieoagulation therapy, and the clinical use of which remains to be further standardized in China.
出处 《中国医院用药评价与分析》 2008年第8期576-579,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 香豆素 华法林 抗凝治疗 临床应用 评价 Coumarin Warfarin Anticoagulation therapy Clinical use Evaluation
  • 相关文献

参考文献23

  • 1李端.药理学[M].第5版.北京:人民卫生出版社,2003:474.
  • 2Gage BF. Pharmacogenetics - based coumarin therapy [ J ]. Hematology Am Soc Hematol Educ Program ,2006:467.
  • 3Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORCI( - 1639G > A) and CYP2C9 genotypes[J]. Clin Chem,2007,53(7) : 1 199.
  • 4Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African - American and European-American patients on warfarin [ J ]. Clin Pharmacol Ther , 2008 , 83 ( 2 ) :312.
  • 5Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance [ J ]. Clin Pharmacol Ther, 2002,72(6) :702.
  • 6Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2[J]. Nature,2004,427(6 974) :537.
  • 7Rieder MJ, Riener AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose[ J ].N Engl J Med ,2005,352(22) :2 285.
  • 8Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[ J]. Chest ,2004,126(3 Suppl) :204s.
  • 9Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy [ J ]. Chest, 2001,119 (suppl) : 22S.
  • 10Spyropoulos AC. Managing oral anticoagulation requires expert experience and clinical evidence[ J ]. J Thromb Thrombolysis, 2006,21(1) :91.

二级参考文献36

  • 1王海鹰,荆志成,李崇剑,王建德,徐希奇,邓可武.肺栓塞患者华法林抵抗现象一例及文献回顾[J].中华心血管病杂志,2004,32(11):1039-1040. 被引量:6
  • 2胡荣,杜昕,马长生.华法林在房颤抗凝治疗中的应用[J].药物不良反应杂志,2004,6(6):366-368. 被引量:8
  • 3张海英,张斌,李玉珍.华法林的相互作用及其安全应用[J].药物不良反应杂志,2007,9(2):112-116. 被引量:65
  • 4Ansell J,Hirsh J,Poller L,et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):204s-233s.
  • 5Miners JO,Birkett DJ.Cytochrome P4502C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol,1998,45(6):525-538.
  • 6Scordo MG,Pengo V,Spina E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther,2002,72(6):702-710.
  • 7Palkimas MP,Skinner HM,Gandhi PJ,et al.Polymorphism induced sensitivity to warfarin:a review of the literature[J].J Thromb Thrombolysis,2003,15(3):205-212.
  • 8Furuya H,Fernandez-Salguero P,Gregory W,et al.Gennetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J].Pharmacogenetics,1995,5(6):389-392.
  • 9Aithal GP,Day CP,Kesteven PJ,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarindose requirement and risk of bleeding complications[J].Lancet,1999,353(9154):717-719.
  • 10Higashi MK,Veenstra DL,Kondo LM,et al.Association between CYP2C9 genetic variants and antcoagula tionrelated outcomes during warfarin therapy[J].JAMA,MA,2002,287(13):1690-1698.

共引文献117

同被引文献63

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部